MediciNova (NASDAQ:MNOV - Get Free Report) is projected to issue its quarterly earnings data before the market opens on Thursday, May 8th. Analysts expect the company to announce earnings of ($0.14) per share for the quarter.
MediciNova (NASDAQ:MNOV - Get Free Report) last released its quarterly earnings results on Wednesday, February 19th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.06). On average, analysts expect MediciNova to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
MediciNova Stock Down 0.7 %
Shares of NASDAQ MNOV traded down $0.01 during trading on Tuesday, reaching $1.50. 2,218 shares of the stock were exchanged, compared to its average volume of 38,378. The business's 50-day moving average price is $1.47 and its 200 day moving average price is $1.78. The company has a market capitalization of $73.57 million, a price-to-earnings ratio of -6.52 and a beta of 0.46. MediciNova has a twelve month low of $1.12 and a twelve month high of $2.55.
Analyst Ratings Changes
MNOV has been the subject of a number of recent analyst reports. StockNews.com started coverage on MediciNova in a research note on Friday. They set a "hold" rating for the company. D. Boral Capital reiterated a "buy" rating and issued a $9.00 price target on shares of MediciNova in a report on Wednesday, April 9th.
Read Our Latest Stock Analysis on MediciNova
MediciNova Company Profile
(
Get Free Report)
MediciNova, Inc, a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID.
Featured Articles
Before you consider MediciNova, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MediciNova wasn't on the list.
While MediciNova currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
